NEW Technology offer - sFIS - A functional biomarker modality for capturing peripheral immune signalling in patients with cancer for reliable immune-stratification
The KU Leuven Laboratory of Cell Stress & Immunity (CSI) presents a first-in-class non-invasive (blood/serum-level), functional immunological screening assay to predict cancer patient survival, malignancy risk and response to therapies. This in vitro assay is based on patient serum-induced dynamic NFkB and IFN signaling in human myeloid cells as read-out of patient overall immunological status.
Check out the technology, its advantages and applications.
Get in touch with us if you’re interested in this technology!
The CSI lab is embedded within the Department of Cellular & Molecular Medicine (CMM), at KU Leuven. The CSI lab aims to specialize in reverse translational approaches to hasten progress in immuno-oncology and help improve therapeutic outlook for cancer patients, in close collaboration with leading researchers, immunologists, and oncologists.